Case reportBreast abscess due to Finegoldia magna in a non-puerperal women
Introduction
Finegoldia magna (formerly Peptostreptococcus maguns) was firstly described as Diplococcus magnus in 1933 [1] and reclassified in the current genus in 1999 by Murdoch and Shah [2]. This microorganism is the most common species of Gram-positive anaerobic cocci (GPAC) isolated in human clinical specimens mainly within polymicrobial infections, and they are especially associated with soft tissue and bone/joint infections [3]. Moreover, several case reports causing a wide variety of infections have been published after isolation in pure culture [4], [5], [6], [7].
We have recently diagnosed an uncommon case of breast abscess caused by F. magna in a non-puerperal patient. To our knowledge, only two cases have been previously described in the medical literature [8], [9], however, our case was caused by clindamycin resistant strain of F. magna and was responsible for the treatment failure of clindamycin oral therapy.
Section snippets
Case report
A 46-year-old women came to the Gynaecology Emergency Department in February 2016 due to four days history of pain and a nodular lesion in the left breast. Her clinical history was unremarkable except for a fibrocystic mastopathy for over 10 years. In the physical examination the presence of a fluctuating abscessed mass in the left breast was observed. The patient was in treatment with clindamycin orally (450 mg/8 h) and analgesics for 4 days, prescribed by his primary care doctor. The patient
Discussion
F. magna is probably both the most common and the most pathogenic GPAC found in human clinical specimens [3], being the species most frequently isolated in pure culture from a wide variety of clinical samples [4], [5], [6], [7]. This microorganism is part of the normal biota specially of the skin, gastrointestinal and female genitourinary tracts and less frequently of the oral cavity [12].
Several studies have currently involved the anaerobic bacteria in the aetiology of the non-puerperal breast
Conflict of interest
Authors declare no conflict of interest.
Funding
None.
References (19)
- et al.
Reclassification of Peptostreptococcus magnus (Prevot 1933) Holdeman and Moore 1972 as Finegoldia magna comb. nov. and Peptostreptococcus micros (Prevot 1933) Smith 1957 as Micromonas micros comb. nov
Anaerobe
(1999) - et al.
Case report: anaerobic meningitis caused by Peptostreptococcus magnus after head and neck surgery
Am. J. Med. Sci.
(1994) - et al.
Antibiotic susceptibility profiles of anaerobic pathogens in The Netherlands
Anaerobe
(2015) - et al.
Evaluation of the routine antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015
Anaerobe
(2017) - et al.
European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci
Int. J. Antimicrob. Agents
(2008) Ètudes des systématique bactérienne. I. Lois générales. II. Cocci Anaérobies
Ann. Sci. Nat.
(1933)- et al.
Peptococcus magnus: a significant human pathogen
Ann. Intern. Med.
(1980) - et al.
Peptococcus magnus endocarditis
South. Med. J.
(1985) - et al.
Peptostreptococcus magnus septic arthritis – a report and review of the English literature
J. Rheumatol.
(1988)
Cited by (6)
“Breast abscess in a male patient due to Finegoldia magna and Bifidobacterium scardovii: An unusual entity”
2022, AnaerobeCitation Excerpt :It is the most pathogenic anaerobic organism which is known to cause diverse clinical infections and is often isolated in pure cultures from clinical specimens. There are former reports of F. magna being isolated from non-puerperal breast abscesses in females [3,9,10]. Gram stain showing Gram-positive cocci arranged in pairs and mostly in tetrads with a diameter of 0.8–1.6 μm could help in presumptive identification of F. magna in clinical specimens [10,11].
Antimicrobial susceptibility and clinical findings of significant anaerobic bacteria in southern Spain
2019, AnaerobeCitation Excerpt :Among GPACs, resistance to penicillin was found for 25% of Peptostreptococcus isolates but for no isolates of Finegoldia, Peptoniphilus, or Parvimonas. High resistance rates to clindamycin were found for F. magna (54%) and Peptoniphilus spp. (38%) [11]. High resistance to metronidazole was found for two strains of F. magna (MIC > 256 μg/mL) and one isolate of P. harei (MIC 6 μg/mL) [12].
One case report of the humerus osteomyelitis caused by Finegoldia magna and literature review
2021, Chinese Journal of Infection and ChemotherapyRisk factors, changes in serum inflammatory factors, and clinical prevention and control measures for puerperal infection
2020, Journal of Clinical Laboratory Analysis